Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Taiwan to ban food-waste pig feeding from 2027, with 1-year transition
12/04/2025 06:39 PM - Business
Taiwan and India to build 'resilient' supply chain: MOEA
12/04/2025 05:47 PM - Society
Space weather disturbance may disrupt satellite, radio communications
12/04/2025 05:45 PM - Science & Tech
Tokyo Electron vows to tighten compliance after Taiwan unit indicted
12/04/2025 04:03 PM - Politics
Military preparedness 'best way to avoid war': President Lai
12/04/2025 02:49 PM